ORTX - Orchard Therapeutics plc Stock Price, Fair Value and News

$16.70

Market Closed

ORTX Stock Valuation Analysis

Valuation

Max Portfolio %

ORTX Price Action

ORTX RSI Chart

ORTX Stock Valuation Analysis

Valuation

Max Portfolio %

ORTX Valuation

ORTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ORTX Fundamentals

ORTX Revenue

ORTX Earnings

ORTX Profitability

ORTX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	18.4M	21.3M	21.8M	0
2022	7.2M	11.6M	16.2M	22.7M
2021	0	0	3.8M	3.7M
2020	0	3.8M	5.1M	3.2M
2019	0	0	3.3M	4.6M
2018	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Orchard Therapeutics plc

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

CEO	Dr. Bobby Gaspar M.D., Ph.D.
WEBSITE	orchard-tx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	166